Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Equities research analysts at HC Wainwright lowered their FY2024 earnings per share estimates for Fennec Pharmaceuticals in a research note issued to investors on Tuesday, December 17th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.18) per share for the year, down from their prior estimate of $0.11. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.01 EPS and FY2025 earnings at ($0.55) EPS.
Separately, Stephens raised shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th.
View Our Latest Research Report on Fennec Pharmaceuticals
Fennec Pharmaceuticals Price Performance
Shares of TSE FRX traded up C$0.34 during midday trading on Thursday, hitting C$8.46. The stock had a trading volume of 657 shares, compared to its average volume of 1,991. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. Fennec Pharmaceuticals has a 1 year low of C$5.65 and a 1 year high of C$15.43. The company has a market capitalization of C$231.47 million, a PE ratio of 84.60 and a beta of 0.25. The stock has a 50 day simple moving average of C$7.01 and a 200-day simple moving average of C$7.68.
Insiders Place Their Bets
In related news, Senior Officer Robert Christopher Andrade bought 15,816 shares of the stock in a transaction on Monday, November 18th. The stock was bought at an average price of C$3.43 per share, with a total value of C$54,248.88. 16.20% of the stock is owned by insiders.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
See Also
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
